Financial Performance - The company's revenue for Q1 2025 was ¥114,446,404.92, a decrease of 17.10% compared to ¥138,059,120.72 in the same period last year[5] - Net profit attributable to shareholders was ¥10,326,085.35, down 72.38% from ¥37,381,597.20 year-on-year[5] - Basic earnings per share fell by 69.23% to ¥0.04 from ¥0.13 in the previous year[5] - Total operating revenue decreased to ¥114,446,404.92 from ¥138,059,120.72, a decline of approximately 17.1% year-over-year[20] - Net profit for the period was ¥10,326,085.35, down from ¥37,381,597.20, a decrease of approximately 72.3% year-over-year[21] - The total comprehensive income for the period was ¥10,326,085.35, down from ¥37,381,597.20, reflecting a decrease of approximately 72.3% year-over-year[21] - Basic and diluted earnings per share decreased to ¥0.04 from ¥0.13, a decline of about 69.2% year-over-year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 57.74%, amounting to ¥6,056,981.76 compared to ¥14,331,076.29 in Q1 2024[11] - Cash and cash equivalents at the end of the period were ¥494,729,887.37, down from ¥1,663,102,024.22, a decrease of approximately 70.3% year-over-year[24] - The company's cash and cash equivalents decreased to ¥494,729,887.37 from ¥543,139,791.63, representing a decline of approximately 8.5%[16] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥2,471,565,643.49, a slight decrease of 0.69% from ¥2,488,655,694.01 at the end of the previous year[5] - Total current assets amounted to ¥1,859,505,802.43, slightly down from ¥1,874,616,455.24, indicating a decrease of about 0.8%[16] - Total liabilities decreased to ¥150,658,217.06 from ¥178,967,160.85, a reduction of approximately 15.8%[17] - The company's total assets stood at ¥2,471,565,643.49, down from ¥2,488,655,694.01, indicating a decrease of about 0.7%[17] - Non-current assets totaled ¥612,059,841.06, slightly down from ¥614,039,238.77, reflecting a decrease of approximately 0.3%[17] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 35.76%, reaching ¥66,014,945.08 compared to ¥48,626,872.60 in the previous year[9] - Accounts receivable increased to ¥66,014,945.08 from ¥48,626,872.60, reflecting a growth of approximately 35.7%[16] - Inventory decreased to ¥133,728,313.29 from ¥137,851,042.47, showing a decline of about 3.0%[16] Research and Development - Research and development expenses decreased by 39.87% to ¥6,579,414.49 from ¥10,942,220.83 in Q1 2024[10] - Research and development expenses decreased to ¥6,579,414.49 from ¥10,942,220.83, a reduction of about 39.5% year-over-year[20] Government Subsidies and Financial Improvements - The company received government subsidies amounting to ¥1,620,203.03, an increase of 170.27% compared to ¥599,479.25 in the same period last year[10] - Financial expenses showed a significant improvement, with a net income of -¥2,483,621.83 compared to -¥17,739,443.07 in the previous period[20] - The company recorded a fair value change income of ¥7,074,652.79, up from ¥947,916.62, indicating a substantial increase[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,753, with the largest shareholder holding 38.25% of the shares[12] Reporting and Accounting Standards - The first quarter report of Hubei Hendi Pharmaceutical Co., Ltd. is unaudited[25] - The new accounting standards will be implemented starting from 2025[25] - The financial statement items related to the first year of the new accounting standards will be adjusted[25] - The board of directors announced the first quarter report on April 25, 2025[25]

二、监事会会议审议情况 证券代码：301211 证券简称：亨迪药业 公告编号：2025-015 湖北亨迪药业股份有限公司 第二届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届监事会第十二次会 议于 2025 年 4 月 15 日以电话及邮件方式送达至全体监事，本次会议于 2025 年 4 月 25 日以现场方式召开。本次会议应参会监事 3 人，实际参会监事 3 人。会 议由监事会主席陈吉人先生召集并主持。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》和《公司章程》的有关规定，会议合法、有效。 会议审议并通过了如下议案： 1、审议通过了《2025 年一季度报告》 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）刊载的《2025 年一季度报告》。 表决结果：3 票同意、0 票反对、0 票弃权。该项议案获审议通过。 2、关于对 2025 年一季度报告的审核意见的议案 经审核，监事会认为董事会编制和审核的公司《2025 年一季度 ...

会议审议并通过了如下议案： 1、审议通过《2025 年一季度报告》 证券代码：301211 证券简称：亨迪药业 公告编号：2025-014 湖北亨迪药业股份有限公司 第二届董事会第十三次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第十三次会 议于 2025 年 4 月 15 日以电话及邮件方式送达至全体董事，本次会议于 2025 年 4 月 25 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人。本次会议由公司董事长程志刚主持，公司监事、高级管理人员列席会议。本 次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 2025 年 4 月 25 日 公司《2025 年一季度报告》符合法律法规，报告内容真实、准确、完整地 反映了公司 2025 年一季度的经营情况，不存在虚假记载、误导性陈述或者重大 遗漏。 具体内容详见公司同日在巨潮资讯网（www.cnin ...

Policy Developments - Seven departments, including the Ministry of Industry and Information Technology, issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", emphasizing the integration of artificial intelligence across the pharmaceutical supply chain [1] Drug and Device Approvals - Kangtai Biological announced that its subsidiary Minhai Biological's application for the marketing authorization of an adsorbed tetanus vaccine has been accepted by the National Medical Products Administration [2] - Hendi Pharmaceutical received approval for the marketing application of arginine ibuprofen, a non-steroidal anti-inflammatory drug with superior solubility and faster absorption compared to regular ibuprofen [3] - Tianyao Pharmaceutical's subsidiary obtained a drug registration certificate for injectable hydrocortisone sodium succinate, used for critical conditions such as allergic shock and severe adrenal insufficiency [4] Financial Reports - Wantai Biological reported a net loss of 52.78 million yuan in Q1 2025, with revenue of 401 million yuan, a year-on-year decline of 46.76%, primarily due to market adjustments and government procurement impacts [5] - Heng Rui Pharmaceutical's Q1 2025 report showed a revenue of 7.206 billion yuan, a year-on-year increase of 20.14%, and a net profit of 1.874 billion yuan, up 36.9%, largely due to a licensing payment from IDEAYA [6] - Kingstone Pharma reported a revenue of 291 million yuan in Q1 2025, down 19.65%, with a net profit of 62.85 million yuan, a decrease of 30.02% [8] - Baijun Medical achieved a revenue of 100 million yuan in Q1 2025, a 31.3% increase, with a net profit of 32.50 million yuan, up 290.69%, driven by stable sales of existing products and successful new product launches [9] Capital Market Activities - Tonghe Pharmaceutical plans to invest 11 million yuan to increase its stake in Hangzhou Boya Biomedical Co., Ltd., raising its ownership from 16.34% to 24.93% [10] - Chengyuan Biotechnology announced the completion of several million yuan in equity financing, aimed at upgrading its gene synthesis technology platform [11] Industry Developments - Zhang Wenhong's team announced significant progress in developing a broad-spectrum antiviral drug for monkeypox, which is set to enter clinical approval stages [12] - Qianxin Biotechnology signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting global exclusive rights for development and commercialization [13] Public Sentiment Alerts - Weiming Pharmaceutical announced that its important subsidiary, Tianjin Weiming, was suspended from production and sales, which could trigger further risk warnings if production does not resume within three months [14]

Core Viewpoint - The fluctuating tariff policies in the U.S. have created a challenging environment for the ibuprofen market, with Hendi Pharmaceutical facing significant declines in revenue and profit due to market saturation and external pressures [2][6]. Financial Performance - Hendi Pharmaceutical reported a revenue of 446 million yuan in 2024, a year-on-year decline of 32.75%, marking the largest drop since data tracking began [2]. - The company's net profit attributable to shareholders was 92 million yuan, down 48.02% year-on-year, with a non-recurring net profit of 73 million yuan, down 57.14% [2]. - The raw material drug segment, primarily ibuprofen, accounted for nearly 80% of the company's revenue, making it difficult to pivot to other business areas in the short term [2][4]. Market Dynamics - The demand for ibuprofen surged during the pandemic, peaking in 2023 with revenues of 663 million yuan, but fell sharply in 2024, dropping below levels seen six years prior [3]. - The raw material drug segment's revenue in 2024 was 356 million yuan, a decrease of 35.78%, with a significant drop in sales volume by 37.51% to 2,222.35 tons [4][5]. - The gross margin for the raw material drug segment fell from 36.11% to 21.18% in 2024, indicating increased cost pressures [4]. Business Strategy - Hendi Pharmaceutical has been developing a range of ibuprofen derivative products to maximize market value, including right-handed ibuprofen, which saw a sales increase of 11.43% to 189.45 tons [4][5]. - The company's formulation business, which generated 85 million yuan in 2024, also faced a decline of 17.57% year-on-year, with a gross margin decrease to 59.48% [5]. - The formulation business remains closely tied to ibuprofen, limiting its ability to act as a buffer against market volatility [5]. Industry Challenges - Hendi Pharmaceutical faces intense competition in the global ibuprofen market, with prices remaining low due to market saturation and external factors such as U.S. tariff policies [6][8]. - The company has decided to terminate its planned expansion project for ibuprofen production, reallocating funds to other development projects instead [7][8]. - The U.S. tariff policies have created uncertainty, particularly affecting exports to key markets like India, despite Hendi's low direct exposure to U.S. sales [8][9].

亨迪药业：公司获得化学原料药精氨酸布洛芬上市申请批准通知书 智通财经4月24日电，亨迪药业(301211.SZ)公告称，公司近日收到国家药品监督管理局核准签发的关于 精氨酸布洛芬的《化学原料药上市申请批准通知书》。精氨酸布洛芬是一种非甾体抗炎药，其水溶性优 于普通布洛芬，吸收更快，起效更迅速。该原料药的上市申请批准通知书丰富了公司产品种类，有利于 提升在化学原料药领域的市场竞争力。 ...

湖北亨迪药业股份有限公司 证券代码：301211 证券简称：亨迪药业 公告编号：2025-013 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于精氨酸布洛芬（以下简称"药品"）的《化学原料药上市 申请批准通知书》（证书编号：2025YS00322）。现将有关情况公告如下： 一、药品的基本情况 药品名称：精氨酸布洛芬 登记号：Y20240000003 规格：15kg/桶 生产企业：湖北亨迪药业股份有限公司 申请事项：境内生产化学原料药上市申请 二、药品的其他相关情况 精氨酸布洛芬是一种非甾体抗炎药（NSAID），是布洛芬与精氨酸结合形成 的盐。其主要用途和特点为镇痛、抗炎、解热以及剂型优势，精氨酸布洛芬的水 溶性优于普通布洛芬，因此吸收更快，起效更迅速。 公司精氨酸布洛芬原料药于 2024 年 1 月申报，近日获得国家药品监督管理 局下发的《化学原料药上市申请批准通知书》。该原料药在 CDE 原辅包登记信 息平台上显示状态为"A ...

湖北亨迪药业股份有限公司 2024 年年度财务报告 1 一、审计报告 | 审计意见类型 | 标准的无保留意见 | | --- | --- | | 审计报告签署日期 | 2025 年 04 月 23 日 | | 审计机构名称 | 大信会计师事务所（特殊普通合伙） | | 审计报告文号 | 大信审字[2025]第 2-00221 号 | | 注册会计师姓名 | 张文娟、潘杨州 | 审计报告正文 审 计 报 告 大信审字[2025]第 2-00221 号 湖北亨迪药业股份有限公司全体股东： 一、审计意见 我们审计了湖北亨迪药业股份有限公司（以下简称"贵公司"）的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并 及母公司股东权益变动表，以及财务报表附注。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对财务报表审 计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职业道德守则，我们独立 于贵公司，并履行了职业道德方面的其他责任。 我们相信，我们获取的审计证据是 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-007 湖北亨迪药业股份有限公司 关于续聘公司 2025 年度审计机构的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第二届董事会第十二次会议，审议通过了《关于续聘公 司 2025 年度审计机构的议案》，本议案尚需提交股东大会审议。现 就相关事宜公告如下： 一、拟聘用会计师事务所事项的情况说明 经公司董事会审计委员会提议，公司拟续聘大信会计师事务所 （特殊普通合伙）（以下简称"大信事务所"）负责公司 2025 年度 审计工作。大信事务所具有从事证券业务资格及从事上市公司审计工 作的丰富经验和职业素养，该所在担任公司审计机构期间，恪尽职守， 遵循独立、客观、公正的执业准则，较好地完成了公司委托的各项工 作。因此，董事会同意续聘大信会计师事务所（特殊普通合伙）为公 司 2025 年度审计机构，聘期一年。自公司 2024 年年度股东大会审议 通过之日起生效。 二、拟续聘任会计师事务所的基本信息 （一）机构信息 1 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-012 湖北亨迪药业股份有限公司 关于会计估计变更的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 本次会计估计变更自第二届董事会第十二次会议审议通过之日起执行。 本次会计估计变更是湖北亨迪药业股份有限公司（以下简称"公司"）采用 未来适用法进行会计处理，无需对已披露的财务报告进行追溯调整，对公司以往 各年度财务状况和经营成果不会产生影响。 本次会计估计变更后，具体影响取决于研发项目未来开发阶段实际发生并满 足资本化条件的支出，尚无法准确估计具体影响。 一、会计估计变更的概述 （一）本次会计估计变更原因 为了优化公司产品结构，丰富公司产品的种类，以适应国内外市场需求，近 年来公司持续加大研发投入，根据《企业会计准则第 28 号－会计政策、会计估 计变更和会计差错》的相关规定，并参考同行业上市公司的研发支出资本化情况， 公司决定对研发支出资本化时点的估计进行变更，使公司研发费计量更加符合公 司实际情况。 （二）本次会计估计变更日期 自第二届董事会第十二次会议审议通过之日起执行 ...